Nodal marginal zone B-cell lymphoma
MONDO:0019465Nodal marginal zone B-cell lymphoma is a rare, indolent B-cell non-Hodgkin lymphoma, characterized by abnormal clonal proliferation of mature B-lymphocytes with involvement of the lymph nodes, sometimes the bone marrow, and rarely the blood. Clinically it presents with disseminated peripheral, abdominal and/or thoracic lymphadenopathy. Cytopenia and bulky tumors (greater than 5 cm) are rare. Association with Hepatitis C virus and chronic inflammation has been reported.
Also known as: Monocytoid B-cell lymphoma, NMZL, nodal marginal zone B-cell lymph., nodal marginal zone B-cell lymphoma, nodal marginal zone lymphoma
2015 clinical trials for this condition and its sub-types, 16 tagged with Nodal marginal zone B-cell lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New hope for tough lymphoma: drug combo plus stem cell transplant shows promise
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab to standard chemotherapy and a stem cell transplant can help people with large B-cell lymphoma that has come back or not responded to treatment. About 25 adults will receive the combination, followed by more epcoritamab after t…
Phase 2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New trial aims to bring targeted lymphoma drugs to minority patients
Disease control Recruiting nowThis phase 1 trial is testing a combination of two targeted drugs, zanubrutinib and sonrotoclax, in people from underrepresented racial and ethnic groups who have relapsed or refractory B-cell non-Hodgkin lymphoma. The study aims to see if this treatment is feasible and safe for …
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New drug SGR-1505 enters early human testing for blood cancers
Disease control Recruiting nowThis early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. Participants will receive the d…
Phase 1 • Sponsor: Schrödinger, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Engineered immune cells take aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new treatment for people with certain types of lymphoma or leukemia that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goal is t…
Phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for lymphoma patients: experimental drug epcoritamab enters phase 2 trial
Disease control Recruiting nowThis study tests whether the investigational drug epcoritamab can help people with newly diagnosed marginal zone lymphoma, a slow-growing blood cancer. About 25 adults will receive the drug and be monitored for complete remission after 12 cycles. The goal is to see if this treatm…
Phase 2 • Sponsor: Izidore Lossos, MD • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Scientists dive into DNA of rare lymphoma to predict outcomes
Knowledge-focused Recruiting nowThis study looks at tumor samples from 300 people with nodal marginal zone lymphoma, a rare blood cancer. Researchers want to find genetic patterns that help predict how the disease will behave. The goal is to better understand the disease and improve future treatment decisions.
Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC